QSAM 4.95 QSAM Biosciences, Inc.
| Range: | 4.1-16600.0 | Vol Avg: | 6095 | Last Div: | 0 | Changes: | -16591.7 |
| Beta: | 1.81 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Mon Aug 13 2012 | Empoloyees: | 4 | ||
| CUSIP: | 74738N103 | CIK: | 0001310527 | ISIN: | US74738N2027 | Country: | US |
| CEO: | Mr. Douglas R. Baum | Website: | https://qsambio.com | ||||
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer and related diseases. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow